Benzydamine Oromucosal Solution in Oral Mucositis (BOOM) (BOOM)

Phase IV Study on the Feasibility of a Preventative/Therapeutic Approach With Benzydamine Oromucosal Solution in Radiation-induced Oral Mucositis (OM) in Patients With Head and Neck Cancer (HNC)

The aim of the present study is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with head and neck cancer.

Study Overview

• Status: Completed
• Conditions: Head and Neck Cancer; Radiation-Induced Mucositis
• Intervention / Treatment: Drug: Benzydamine Hydrochloride 0.15% w/v oromucosal solution

Detailed Description

This is a phase IV clinical study whose aim is to collect data on the feasibility of a preventative/therapeutic approach of radiation-induced oral mucositis with benzydamine oromucosal solution (mouthwash) in patients with Head and Neck cancer.

Benzydamine mouthwash is considered the gold standard among anti-inflammatory agents in the management of oral mucositis in cancer patients.

The 2014 mucositis guidelines recommended benzydamine mouthwash for the prevention of radiation-induced oral mucositis among Head and Neck Cancer patients treated with moderate doses of radiation therapy. The updated 2019 guidelines not only confirm the existing guidelines proving new evidences, but also recommend to use benzydamine as preventative treatment of radiation-induced Oromucositi among Head and Neck Cancer. patients treated with radiation therapy with/without systemic concurrent treatments and confirm benzydamine mouthwash as the only anti-inflammatory agent with evidence in prevention of oral mucositis to date.

• Study Type: Interventional
• Enrollment (Actual): 100
• Phase: Phase 4

Contacts and Locations

Study Locations

• Hungary
  • Budapest, Hungary, 1122
    • Orszagos Onkologiai Intezet, Gyogyszertar
  • Debrecen, Hungary, 4032
    • Debreceni Egyetem Klinikai Kozpont, Intezeti Gyogyszertar
  • Győr, Hungary, 9024
    • Petz Aladar Egyetemi Oktato Korhaz, Intezeti Gyogyszertar,
  • Kaposvár, Hungary, 7400
    • Somogy Megyei Kaposi Mor Oktato Korhaz - Eszaki Tomb, 1. Emelet, 4. Szarny, Klinikai - Vizsgalati Egyseg.
  • Nyíregyháza, Hungary, 4400
    • Szabolcs-Szatmar-Bereg Megyei Korhazak es Egyetemi Oktatokorhaz, Josa Andras Oktatokorhaz Klinikai Kutatasi Osztaly
  • Veszprém, Hungary, 8200
    • Csolnoky Ferenc Korhaz, Onkologiai Centrum Sugarterapias Osztaly
• Poland
  • Bydgoszcz, Poland, 85-796
    • Centrum Onkologii im. Prof. Franciszka Łukaszczyka Apteka Szpitalna
  • Gdynia, Poland, 81-519
    • Szpitale Pomorskie Sp. z o. o.,
  • Siedlce, Poland, 08-110
    • Mazowiecki Szpital Wojewódzki im. św. Jana Pawła II w Siedlcach -
  • Łódź, Poland, 95-513
    • Wojewodzkie Wielospecjalistyczne Centrum Onkologii I Traumatologii im. M. Kopernika w Lodzi, - Lódzkie

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female patients of any ethnic origin ≥18 years of age.
• Patients diagnosed with stage III or IV Head and Neck cancer (histologic or cytologic diagnosis), according to VIII AJCC staging system, who are candidate and are about to start RT, with or without concomitant CT, with curative intent, either with exclusive or postoperative intent.
• Eastern Cooperative Oncology Group (ECOG) performance status with a score of 0, or 1, or 2.
• Patients legally capable of giving their consent to participate in the study and available to sign and date the written informed consent and the Declaration of consent for the processing of personal data.

• Women of childbearing potential or with no menses for a period < 12 months must have a negative pregnancy test at Visit 0 and have to agree not to start a pregnancy from the signature of the informed consent up to the end of the study, using an appropriate birth control method, such as combined oestrogen-progestin containing hormonal contraceptives (e.g., oral, injectable, transdermal), progestin-only hormonal contraceptives (e.g., oral, injectable, implantable), intrauterine device (IUD) or Intrauterine hormone-releasing System (IUS) in combination with male condom, bilateral tubal occlusion, vasectomised partner, sexual abstinence. The following definitions will be considered:

  • Woman of childbearing potential (WOCBP): i.e., fertile, following menarche and until becoming post-menopausal, unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy.

Exclusion Criteria:

• Patients with reported allergy to benzydamine or another component of the formulation used.
• Any contraindications listed in the local product's Summary of Product Characteristics (SmPCs).
• Patients with prior head and neck RT (in the previous 6 months), or patient who received a palliative treatment.
• Patients with distant metastatic disease and/or severe cognitive impairment and/or clinically symptomatic brain metastases and/or patients with significant comorbid conditions.
• Patients with mucositis due to other medical conditions (e.g., gastro-oesophageal reflux, autoimmune disease, etc.).
• Patients who use other oromucosal products (over the counter or prescription) for the same disease.
• Prescription of other rinses (anaesthetics like "magic mouthwashes" or others), except from sodium bicarbonate rinses.
• Use of chlorhexidine, other anti-inflammatory mouthwashes solutions, misoprostol, granulocyte macrophage colony-stimulating factor (GM-CSF) and sucralfate gel.
• Employment of antifungal or antibiotic drugs as prophylaxis for mucositis; any therapeutic use in case of overt clinical infections is allowed.
• Patients treated with other therapies that can cause mucositis, except for the therapies for their primary condition.
• Patients treated with any topical anti-inflammatory/analgesic products for the mucositis.
• Any other product that can interfere with the evaluation of pain or inflammatory state, according to the Investigator's assessment.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm

Intervention / Treatment

Experimental: Benzydamine Hydrochloride 0.15% w/v oromucosal solution; Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A., is assigned to the patients for radiation-induced oromucositis. The patients take at home 15 ml (1 tablespoon) of concentrated or diluted (with water) mouthwash 2-3 times a day, but not more than 5 times a day, washing the mouth and throat for 20-30 seconds, according to the Investigator's indications and the local product's SmPC. In Hungary, the therapy should started with diluted product (15 ml of water + 15 ml of concentrated solution). After that, gargling can be continued with 15 ml (1 tablespoon) of concentrated mouthwash, generally 2-3 times a day, but not more than 5 times a day. In Poland, the solution is used 2 to 3 times daily; at a single time, it should be used approximately 15 ml of concentrated or diluted mouthwash with a small amount of water and wash the mouth and throat for 20 to 30 seconds.

Drug: Benzydamine Hydrochloride 0.15% w/v oromucosal solution; Benzydamine Hydrochloride 0.15% w/v oromucosal solution (mouthwash), Angelini Pharma S.p.A.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of responders	The effectiveness of benzydamine oromucosal solution (mouthwash) in the prevention/tratment of radiation-induced oral mucositis in Head and Neck cancer patients is evaluated as the number of responders, expressed in percentage, defined as the number of head and neck cancer patients with oral mucositis pain intensity <5 in the Numeric Rating Scale.	Up to 7 weeks

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of compliant patients to Benzydamine treatment.	The compliance to the treatment is calculated at the end of the study. A patient is considered compliant to the benzydamine treatment if he/she takes ≥80% of the total dose assigned by the Investigator.	Up to 7 weeks
Change score in the World Health Organization oral mucositis grading scale.	The severity of oral mucositis is evaluated using the World Health Organization (WHO) oral mucositis grading scale. The Investigator gives a score corresponding to the grade of mucositis of the patient, from "0" = "None" to "4" = "Life-threatening", "Oral alimentation impossible".	Up to 7 weeks
Number of days of duration of severe oral mucositis.	The duration of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed.	Up to 7 weeks
Time of onset of severe oral mucositis.	Time of onset of severe oral mucositis (grade 3 or 4 on the World Health Organization oral mucositis grading scale) is assessed.	Up to 7 weeks
Percentage change in body weight	The percentage change in body weight from baseline is assessed.	Up to 7 weeks
Number of days of duration of Radiotherapy/Chemotherapy	Radiotherapy/Chemotherapy is assessed as number of days of duration of therapy.	Up to 7 weeks
Number of days of discontinuation of Radiotherapy/Chemotherapy	Radiotherapy/Chemotherapy is assessed in terms of days of therapy discontinuation.	Up to 7 weeks
Dose modifications of Radiotherapy/Chemotherapy	Radiotherapy/Chemotherapy is evaluated as dose modifications of therapy.	Up to 7 weeks
Delays in Radiotherapy/Chemotherapy	Radiotherapy/Chemotherapy is evaluated as days of delay in therapy.	Up to 7 weeks
Number of days of hospitalization.	The healthcare resources consumed in terms of number of days of hospitalization due to oral mucositis are evaluated.	Up to 7 weeks
Change in QoL (EORTC QLQ C-30) from baseline	The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ C-30)	Up to 7 weeks
Change in QoL (EORTC QLQ-H&N35) from baseline	The health-related quality of life is measured using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Head and Neck (EORTC QLQ-H&N35).	Up to 7 weeks
Number and type of opioid analgesics	The use of opioid analgesics prescribed for oral mucositis pain is assessed.	Up to 7 weeks
Frequency of adverse events	AEs occurred during a clinical trial are assessed by the Investigator in terms of seriousness and relationship with the investigational product.	Up to 7 weeks

Collaborators and Investigators

• Sponsor: Aziende Chimiche Riunite Angelini Francesco S.p.A
• Collaborators: PPD

Study record dates

Study Major Dates

• Study Start (Actual): December 6, 2021
• Primary Completion (Actual): September 5, 2022
• Study Completion (Actual): September 5, 2022

Study Registration Dates

• First Submitted: June 23, 2021
• First Submitted That Met QC Criteria: September 14, 2021
• First Posted (Actual): September 24, 2021

Study Record Updates

• Last Update Posted (Actual): November 16, 2022
• Last Update Submitted That Met QC Criteria: November 15, 2022
• Last Verified: November 1, 2022

More Information

Terms related to this study

• Keywords: head and neck cancer; radiation therapy; mouthwash; oral mucositis; oromucosal solution; benzydamine
• Additional Relevant MeSH Terms: Digestive System Diseases; Neoplasms; Neoplasms by Site; Gastrointestinal Diseases; Gastroenteritis; Stomatognathic Diseases; Mouth Diseases; Head and Neck Neoplasms; Mucositis; Stomatitis; Anti-Inflammatory Agents; Benzydamine
• Other Study ID Numbers: 030(Z)WO19247; 2020-003306-32 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No